C.M.L. Driessen

1.0k total citations
39 papers, 421 citations indexed

About

C.M.L. Driessen is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C.M.L. Driessen has authored 39 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 15 papers in Otorhinolaryngology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C.M.L. Driessen's work include Head and Neck Cancer Studies (14 papers), Salivary Gland Tumors Diagnosis and Treatment (9 papers) and Oral health in cancer treatment (8 papers). C.M.L. Driessen is often cited by papers focused on Head and Neck Cancer Studies (14 papers), Salivary Gland Tumors Diagnosis and Treatment (9 papers) and Oral health in cancer treatment (8 papers). C.M.L. Driessen collaborates with scholars based in Netherlands, United Kingdom and Germany. C.M.L. Driessen's co-authors include Floortje Mols, Gerard Vreugdenhil, Carla M.L. van Herpen, Wouter Dercksen, Antoinetta J. M. Beijers, Maike J.M. Uijen, Winette T.A. van der Graaf, A.J.J.M. Vingerhoets, Adriana C. H. van Engen–van Grunsven and J.H.A.M. Kaanders and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

C.M.L. Driessen

36 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C.M.L. Driessen Netherlands	11	230	139	98	90	84	39	421
Emanuela Olmetto Italy	11	134 0.6×	89 0.6×	113 1.2×	15 0.2×	195 2.3×	38	414
Ayşe Nur Demiral Türkiye	13	141 0.6×	66 0.5×	101 1.0×	9 0.1×	197 2.3×	31	402
Umberto Caliceti Italy	13	87 0.4×	352 2.5×	92 0.9×	13 0.1×	101 1.2×	34	485
Lindsay Williams United States	8	195 0.8×	214 1.5×	41 0.4×	50 0.6×	51 0.6×	9	453
René A. Khafif United States	13	104 0.5×	320 2.3×	65 0.7×	19 0.2×	92 1.1×	19	580
Lawrence Oh Australia	12	93 0.4×	192 1.4×	58 0.6×	15 0.2×	60 0.7×	27	431
Mark Kubik United States	13	138 0.6×	330 2.4×	238 2.4×	10 0.1×	81 1.0×	42	504
Jiro Kawamori Japan	13	66 0.3×	97 0.7×	27 0.3×	57 0.6×	93 1.1×	50	369
Ruşen Coşar Türkiye	10	91 0.4×	65 0.5×	9 0.1×	36 0.4×	106 1.3×	41	297
Henrik Baymler Pedersen Denmark	15	144 0.6×	372 2.7×	62 0.6×	6 0.1×	42 0.5×	23	621

Countries citing papers authored by C.M.L. Driessen

Since Specialization

Citations

This map shows the geographic impact of C.M.L. Driessen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.M.L. Driessen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.M.L. Driessen more than expected).

Fields of papers citing papers by C.M.L. Driessen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.M.L. Driessen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.M.L. Driessen. The network helps show where C.M.L. Driessen may publish in the future.

Co-authorship network of co-authors of C.M.L. Driessen

This figure shows the co-authorship network connecting the top 25 collaborators of C.M.L. Driessen. A scholar is included among the top collaborators of C.M.L. Driessen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.M.L. Driessen. C.M.L. Driessen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Driessen, C.M.L., et al.. (2025). Safety of accelerated infusion of nivolumab and pembrolizumab. European Journal of Cancer. 220. 115373–115373.

Verhaegh, Gerald W., Adriana C. H. van Engen–van Grunsven, C.M.L. Driessen, et al.. (2024). A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol. BMC Cancer. 24(1). 1174–1174. 1 indexed citations

Uijen, Maike J.M., C.M.L. Driessen, Steffie M. B. Peters, et al.. (2024). Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study. Theranostics. 14(14). 5388–5399. 3 indexed citations

Verhoeven, Jamie I., Mireille J. M. Broeders, C.M.L. Driessen, et al.. (2023). Association of Stroke at Young Age With New Cancer in the Years After Stroke Among Patients in the Netherlands. JAMA Network Open. 6(3). e235002–e235002. 16 indexed citations

Driessen, C.M.L., Janine Nuver, Mariëtte Labots, et al.. (2023). Abstract CT139: The STELLAR trial: A phase II/III study of high-dose intermittent sunitinib in patients with recurrent glioblastoma. Cancer Research. 83(8_Supplement). CT139–CT139. 1 indexed citations

Verhaegh, Gerald W., et al.. (2023). Retrospective analysis of genetically matched therapies in salivary gland cancer entities using a real-world database in a tertiary salivary gland cancer expertise center.. Journal of Clinical Oncology. 41(16_suppl). 6098–6098. 1 indexed citations

Scheenen, Tom W. J., et al.. (2022). Diffusion imaging could aid to differentiate between glioma progression and treatment-related abnormalities: a meta-analysis. Insights into Imaging. 13(1). 158–158. 12 indexed citations

Uijen, Maike J.M., et al.. (2022). Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma. Oral Oncology. 125. 105703–105703. 19 indexed citations

Broekman, Marike L. D., Filip De Vos, Edwin Cuppen, et al.. (2022). Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study. BMC Medical Genomics. 15(1). 233–233. 5 indexed citations

10.

Willemsen, Anna C. H., Annemieke Kok, Laura W. J. Baijens, et al.. (2021). Development and external validation of a prediction model for tube feeding dependency for at least four weeks during chemoradiotherapy for head and neck cancer. Clinical Nutrition. 41(1). 177–185. 8 indexed citations

11.

Uijen, Maike J.M., Adriana C. H. van Engen–van Grunsven, Yuichiro Tada, et al.. (2020). Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. Cancer Treatment Reviews. 89. 102069–102069. 35 indexed citations

12.

Driessen, C.M.L., Mathijs P. Hendriks, E. Fiets, et al.. (2019). Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study. European Journal of Cancer. 113. 32–40. 10 indexed citations

13.

Herpen, Carla M.L. van, et al.. (2019). Health-related quality of life of patients treated with chemoradiotherapy plus or minus prophylactic antibiotics to reduce the number of pneumonias for locally advanced head and neck cancer, the PANTAP study. Oral Oncology. 96. 105–112. 4 indexed citations

14.

Joerger, Markus, Manuel Haschke, S. Krähenbühl, et al.. (2017). Prognostic impact of drug interactions in patients with advanced cancer. Annals of Oncology. 28. v498–v498. 1 indexed citations

15.

Driessen, C.M.L., Jan Paul de Boer, Hans Gelderblom, et al.. (2017). Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial. Supportive Care in Cancer. 26(4). 1233–1242. 3 indexed citations

16.

Driessen, C.M.L., A.F.M. Snik, Jan Paul de Boer, et al.. (2016). Ototoxicity in locally advanced head and neck cancer (LAHNC) patients (pts) treated with induction chemotherapy (IC) followed by cisplatin-based chemoradiotherapy (CRT). Annals of Oncology. 27. vi341–vi341.

17.

Driessen, C.M.L., Jan Paul de Boer, Hans Gelderblom, et al.. (2015). Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. European Journal of Cancer. 52. 77–84. 31 indexed citations

18.

Driessen, C.M.L., Michelle M. van Rossum, Willeke A.M. Blokx, & Carla M.L. van Herpen. (2013). Skin lesions in a patient with head and neck cancer.. PubMed. 71(9). 481, 485–481, 485. 4 indexed citations

19.

Driessen, C.M.L., et al.. (2011). Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients. Supportive Care in Cancer. 20(4). 877–881. 64 indexed citations

20.

Strasser, Florian, Rolf Oberholzer, David Blum, et al.. (2011). Lenalidomide in solid tumor patients with inflammatory cancer cachexia: A multicenter, randomized, double-blind, proof-of-concept study of fixed dose or CRP-response-guided dose or placebo.. Journal of Clinical Oncology. 29(15_suppl). TPS239–TPS239. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact